Scrutiny and Stock Plummet: ADMA Biologics Faces Investigation Over Revenue Claims
On March 24, 2026, shares of ADMA Biologics, Inc. (NASDAQ: ADMA) took a significant hit of over 16% following the release of a concerning report by short seller Culper Research. The report, titled "ADMA Biologics Inc. (ADMA) Channel Stuffing, an Undisclosed Related Party Distributor, and -3.5% Real Growth in 2025 vs. +20% Reported," raised serious questions regarding the company's financial practices and reporting accuracy. As a result of this scrutiny, Hagens Berman, a national law firm specializing in shareholder rights, has initiated an investigation into ADMA's financial practices and potential violations of federal securities laws.
ADMA Biologics is known for its work in developing and marketing specialty biologics that help treat immunodeficient patients, including its flagship product ASCENIV, aimed at treating Primary Humoral Immunodeficiency. However, the revelations around the company’s financial health painted a troubling picture for investors.
Culper's report highlighted a disturbing increase in ADMA's days sales outstanding (DSO), which leapt from 43 days at the end of 2024 to 113 days by December 31, 2025. This dramatic rise was attributed to practices that suggest potential 'channel stuffing,' wherein the company allegedly induced its distributors to stockpile excess ASCENIV by offering incentives such as rebates and extended payment terms. Such tactics, if verified, could mislead investors by inflating revenue figures that were never actually realized, prompting concerns that ADMA had hidden actual revenue declines behind these manipulated numbers.
The author of the report, Culper, claimed that had ADMA maintained its payment terms without extending them to bolster apparent sales, it would have instead reported a year-over-year revenue decline of 3%, contrary to the claimed 20% growth. The emergence of these allegations prompted Hagens Berman to ask current and former ADMA investors to share their experiences, urging any witnesses with relevant information to reach out. The firm is exploring whether the company's supposed adherence to Generally Accepted Accounting Principles (GAAP) has been compromised and whether there has been any misconduct regarding revenue recognition through undisclosed related-party transactions.
Market reaction to the report was swift and severe. Investors, alarmed by the implications of a potential violation of accounting laws, quickly sold off shares, leading to considerable losses across the board. Analysts noted that this turbulence in ADMA's stock could be linked to an analyst downgrade from overweight to neutral by a prominent market research firm due to these revelations, further impacting investor confidence.
Hagens Berman’s investigation aims to assess whether there is merit to Culper's claims and if ADMA has indeed compromised investor trust through its financial reporting. Reed Kathrein, a partner at Hagens Berman, stated, “We’re investigating Culper’s claims and whether ADMA has violated applicable accounting rules, including revenue recognition rules.”
Investors who witnessed significant losses due to ADMA’s stock drop or who possess critical information regarding the company's practices are encouraged to take action. Hagens Berman is extending an invitation to these parties to share their insights to assist in the investigation and potentially recover losses if wrongdoing is confirmed. Furthermore, individuals with non-public information that could inform the investigation are encouraged to consider the SEC Whistleblower Program, which permits whistleblowers to receive rewards for assisting in the recovery of funds through their disclosures.
As the situation unfolds, stakeholders in ADMA Biologics and potential investors remain on high alert, closely monitoring ongoing developments as Hagens Berman continues its thorough investigation into the matter. The company’s future, along with the well-being of its investors, hangs precariously in this balance, with transparency and integrity in its financial reporting becoming paramount. Investors are left to ponder the implications this scrutiny may have, not only on ADMA but on trust levels within the biopharmaceutical industry at large.
ADMA Biologics is known for its work in developing and marketing specialty biologics that help treat immunodeficient patients, including its flagship product ASCENIV, aimed at treating Primary Humoral Immunodeficiency. However, the revelations around the company’s financial health painted a troubling picture for investors.
Culper's report highlighted a disturbing increase in ADMA's days sales outstanding (DSO), which leapt from 43 days at the end of 2024 to 113 days by December 31, 2025. This dramatic rise was attributed to practices that suggest potential 'channel stuffing,' wherein the company allegedly induced its distributors to stockpile excess ASCENIV by offering incentives such as rebates and extended payment terms. Such tactics, if verified, could mislead investors by inflating revenue figures that were never actually realized, prompting concerns that ADMA had hidden actual revenue declines behind these manipulated numbers.
The author of the report, Culper, claimed that had ADMA maintained its payment terms without extending them to bolster apparent sales, it would have instead reported a year-over-year revenue decline of 3%, contrary to the claimed 20% growth. The emergence of these allegations prompted Hagens Berman to ask current and former ADMA investors to share their experiences, urging any witnesses with relevant information to reach out. The firm is exploring whether the company's supposed adherence to Generally Accepted Accounting Principles (GAAP) has been compromised and whether there has been any misconduct regarding revenue recognition through undisclosed related-party transactions.
Market reaction to the report was swift and severe. Investors, alarmed by the implications of a potential violation of accounting laws, quickly sold off shares, leading to considerable losses across the board. Analysts noted that this turbulence in ADMA's stock could be linked to an analyst downgrade from overweight to neutral by a prominent market research firm due to these revelations, further impacting investor confidence.
Hagens Berman’s investigation aims to assess whether there is merit to Culper's claims and if ADMA has indeed compromised investor trust through its financial reporting. Reed Kathrein, a partner at Hagens Berman, stated, “We’re investigating Culper’s claims and whether ADMA has violated applicable accounting rules, including revenue recognition rules.”
Investors who witnessed significant losses due to ADMA’s stock drop or who possess critical information regarding the company's practices are encouraged to take action. Hagens Berman is extending an invitation to these parties to share their insights to assist in the investigation and potentially recover losses if wrongdoing is confirmed. Furthermore, individuals with non-public information that could inform the investigation are encouraged to consider the SEC Whistleblower Program, which permits whistleblowers to receive rewards for assisting in the recovery of funds through their disclosures.
As the situation unfolds, stakeholders in ADMA Biologics and potential investors remain on high alert, closely monitoring ongoing developments as Hagens Berman continues its thorough investigation into the matter. The company’s future, along with the well-being of its investors, hangs precariously in this balance, with transparency and integrity in its financial reporting becoming paramount. Investors are left to ponder the implications this scrutiny may have, not only on ADMA but on trust levels within the biopharmaceutical industry at large.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.